Q1 FY27 results analysis · July 24, 2026

Laurus Labs Ltd (LAURUSLABS) Q1 FY27 Results Analysis: EBITDA Margin Expands 715 bps, Revenue Grows 29%

+125.5%PAT year on year, Rs. 367.60 Cr
Cofacto ResearchPublished July 24, 20262 min readPositive read
Quick summary

Laurus Labs Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,026.31 Cr (+29.10% YoY) and PAT growth of +125.49% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 24, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 2,026.31 Cr (+29.10% YoY)
PAT (Q1)Rs. 367.60 Cr (+125.49% YoY)
EBITDA margin31.50% (+715 bps YoY)
EPS (Q1)Rs. 6.81 (+125.50% YoY)
Market capRs. 86,504.76 Cr
CMPRs. 1,601.20

Quarter Snapshot

Laurus Labs delivered a strong Q1 with 29% revenue growth, 715 bps EBITDA margin expansion to 31.5%, and PAT more than doubling. Subsidiary profitability surged, and regulatory risk is mitigated by a zero-observation EIR. However, the absence of management guidance and segment-level disclosure limits visibility into the sustainability of the CDMO and ARV trends.

Key Investment Insights

Key Positives

  • Revenue grew 29.1% YoY to Rs.2,026.31 Cr, with sequential acceleration to 11.9% QoQ.
  • EBITDA margin expanded 715 bps YoY to 31.50%, with every cost head improving as a percentage of revenue.
  • PAT attributable to equity holders rose 125.5% YoY to Rs.367.60 Cr, and EPS doubled to Rs.6.81.
  • Subsidiary PAT contribution surged from Rs.5.08 Cr to Rs.77.64 Cr, indicating strong profitability in regulated generics or Laurus Bio.
  • Finance costs fell 18% YoY despite slight QoQ increase, suggesting debt reduction or lower rates.
  • Clean audit opinion with no exceptional items or qualifications.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.